Investing.com -- Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.
Key drivers include rising awareness of obstructive sleep apnea (OSA), market share gains in OSA masks, and operating margin expansion through cost management and product mix. Goldman forecasts mask revenue growth exceeding consensus by 2.4%-10.7% for fiscal 2025-27.
The note highlights ResMed's ongoing innovation, with new mask and accessory launches expected in late 2024, and predicts the company could achieve the upper end of its fiscal 2030 revenue growth target.
Goldman believes CPAP therapy will coexist with GLP-1 drugs for OSA treatment, supported by clinical data and insurance policies. ResMed's app engagement also indicates strong therapy compliance.
The 12-month price target reflects a 30% upside, based on a blend of discounted cash flow and EV/EBIT multiples.
Related Articles
Goldman Sachs starts coverage on ResMed with "buy" rating
Building permits, housing starts data due Friday
State Street, Schlumberger, Regions lead Friday earnings lineup
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.